Incyte Analysts Raise Their Forecasts After Upbeat Q2 Results

Benzinga Earnings07-29 22:53

Incyte Corp. (NASDAQ:INCY) on Tuesday reported better-than-expected second-quarter results and raised its full-year sales guidance.

The biopharmaceutical company reported adjusted earnings of $3.09 per share, beating the analyst consensus estimate of $2.12. Revenue rose 38% year over year to $1.67 billion, topping the consensus estimate of $1.46 billion.

"Our second quarter was marked by broad-based sales growth, continued pipeline progress and strategic business development," Chief Executive Officer Bill Meury said.

Incyte raised its 2026 total net sales guidance to a range of $5.13 billion to $5.26 billion, up from its previous forecast of $4.77 billion to $4.94 billion. However, the updated outlook remains below the analyst consensus estimate of $5.712 billion.

Incyte shares fell 1.7% to trade at $127.75 on Wednesday.

These analysts made changes to their price targets on Incyte following earnings announcement.

HC Wainwright & Co. analyst Mitchell S. Kapoor maintained the stock with a Buy and raised the price target from $140 to $150.
Barclays analyst Etzer Darout maintained the stock with an Overweight rating and raised the price target from $134 to $139.
BMO Capital analyst Evan Seigerman maintained the stock with a Market Perform and raised the price target from $112 to $130.
Guggenheim maintained the stock with a Buy and boosted the price target from $136 to $150

Considering buying INCY stock? Here’s what analysts think:

Photo via Shutterstock

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2655189131?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-29 22:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2655189131","market":"us","top_or_hot":-1,"title":"Incyte Analysts Raise Their Forecasts After Upbeat Q2 Results","media":"Benzinga Earnings","content":"<html><body><p><strong>Incyte Corp.</strong> (NASDAQ:INCY) on Tuesday reported better-than-expected second-quarter results and raised its full-year sales guidance.</p>\n<p>The biopharmaceutical company reported adjusted earnings of $3.09 per share, beating the analyst consensus estimate of $2.12. Revenue rose 38% year over year to $1.67 billion, topping the consensus estimate of $1.46 billion.</p>\n<p>\"Our second quarter was marked by broad-based sales growth, continued pipeline progress and strategic business development,\" Chief Executive Officer Bill Meury said.</p>\n<p>Incyte raised its 2026 total net sales guidance to a range of $5.13 billion to $5.26 billion, up from its previous forecast of $4.77 billion to $4.94 billion. However, the updated outlook remains below the analyst consensus estimate of $5.712 billion.</p>\n<p>Incyte shares fell 1.7% to trade at $127.75 on Wednesday.</p>\n<p>These analysts made changes to their price targets on Incyte following earnings announcement.</p>\n<ul>\n<li>HC Wainwright &amp; Co. analyst Mitchell S. Kapoor maintained the stock with a Buy and raised the price target from $140 to $150.</li>\n<li>Barclays analyst Etzer Darout maintained the stock with an Overweight rating and raised the price target from $134 to $139.</li>\n<li>BMO Capital analyst Evan Seigerman maintained the stock with a Market Perform and raised the price target from $112 to $130.</li>\n<li>Guggenheim maintained the stock with a Buy and boosted the price target from $136 to $150</li>\n</ul>\n<p><strong>Considering buying INCY stock? Here’s what analysts think:</strong></p>\n<figure><img decoding=\"async\" height=\"290\" loading=\"lazy\" sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/07/29105210/image-856-1024x290.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/07/29105210/image-856-1024x290.png 1024w, https://editorial-assets.benzinga.com/wp-content/uploads/2026/07/29105210/image-856-300x85.png 300w, https://editorial-assets.benzinga.com/wp-content/uploads/2026/07/29105210/image-856-768x218.png 768w, https://editorial-assets.benzinga.com/wp-content/uploads/2026/07/29105210/image-856.png 1167w\" width=\"1024\"/></figure>\n<p><em>Photo via Shutterstock</em></p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Incyte Analysts Raise Their Forecasts After Upbeat Q2 Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIncyte Analysts Raise Their Forecasts After Upbeat Q2 Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga Earnings </p>\n<p class=\"h-time\">2026-07-29 22:53</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p><strong>Incyte Corp.</strong> (NASDAQ:INCY) on Tuesday reported better-than-expected second-quarter results and raised its full-year sales guidance.</p>\n<p>The biopharmaceutical company reported adjusted earnings of $3.09 per share, beating the analyst consensus estimate of $2.12. Revenue rose 38% year over year to $1.67 billion, topping the consensus estimate of $1.46 billion.</p>\n<p>\"Our second quarter was marked by broad-based sales growth, continued pipeline progress and strategic business development,\" Chief Executive Officer Bill Meury said.</p>\n<p>Incyte raised its 2026 total net sales guidance to a range of $5.13 billion to $5.26 billion, up from its previous forecast of $4.77 billion to $4.94 billion. However, the updated outlook remains below the analyst consensus estimate of $5.712 billion.</p>\n<p>Incyte shares fell 1.7% to trade at $127.75 on Wednesday.</p>\n<p>These analysts made changes to their price targets on Incyte following earnings announcement.</p>\n<ul>\n<li>HC Wainwright &amp; Co. analyst Mitchell S. Kapoor maintained the stock with a Buy and raised the price target from $140 to $150.</li>\n<li>Barclays analyst Etzer Darout maintained the stock with an Overweight rating and raised the price target from $134 to $139.</li>\n<li>BMO Capital analyst Evan Seigerman maintained the stock with a Market Perform and raised the price target from $112 to $130.</li>\n<li>Guggenheim maintained the stock with a Buy and boosted the price target from $136 to $150</li>\n</ul>\n<p><strong>Considering buying INCY stock? Here’s what analysts think:</strong></p>\n<figure><img decoding=\"async\" height=\"290\" loading=\"lazy\" sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/07/29105210/image-856-1024x290.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/07/29105210/image-856-1024x290.png 1024w, https://editorial-assets.benzinga.com/wp-content/uploads/2026/07/29105210/image-856-300x85.png 300w, https://editorial-assets.benzinga.com/wp-content/uploads/2026/07/29105210/image-856-768x218.png 768w, https://editorial-assets.benzinga.com/wp-content/uploads/2026/07/29105210/image-856.png 1167w\" width=\"1024\"/></figure>\n<p><em>Photo via Shutterstock</em></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"INCY","symbol_name":"因塞特医疗","start_time":0,"source_url":"https://www.benzinga.com/analyst-stock-ratings/price-target/26/07/60764879/incyte-analysts-raise-their-forecasts-after-upbeat-q2-results","article_id":"2655189131","we_media_id":"1052270027","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2655189131","pubTimestamp":1785336806,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Benzinga Earnings","introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"summary":"Incyte Corp. (INCY) reported strong Q2 results, raised full-year sales guidance. CEO cites sales growth, pipeline progress, and business development. Analysts maintain buy ratings with price target increases.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"INCY":"因塞特医疗","BK4588":"碎股","BK4550":"红杉资本持仓","BK4139":"生物科技","BK4585":"ETF&股票定投概念","BK4532":"文艺复兴科技持仓","IDNA":"iShares Genomics Immunology and Healthcare ETF"},"translate_title":"Incyte 分析师在第二季度业绩乐观后上调了预测","themeId":"11c8fbbf839f433c9d274cef5f173382","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IDNA":0.6,"INCY":1.5},"content_text":"Incyte Corp. (NASDAQ:INCY) on Tuesday reported better-than-expected second-quarter results and raised its full-year sales guidance.\nThe biopharmaceutical company reported adjusted earnings of $3.09 per share, beating the analyst consensus estimate of $2.12. Revenue rose 38% year over year to $1.67 billion, topping the consensus estimate of $1.46 billion.\n\"Our second quarter was marked by broad-based sales growth, continued pipeline progress and strategic business development,\" Chief Executive Officer Bill Meury said.\nIncyte raised its 2026 total net sales guidance to a range of $5.13 billion to $5.26 billion, up from its previous forecast of $4.77 billion to $4.94 billion. However, the updated outlook remains below the analyst consensus estimate of $5.712 billion.\nIncyte shares fell 1.7% to trade at $127.75 on Wednesday.\nThese analysts made changes to their price targets on Incyte following earnings announcement.\n\nHC Wainwright & Co. analyst Mitchell S. Kapoor maintained the stock with a Buy and raised the price target from $140 to $150.\nBarclays analyst Etzer Darout maintained the stock with an Overweight rating and raised the price target from $134 to $139.\nBMO Capital analyst Evan Seigerman maintained the stock with a Market Perform and raised the price target from $112 to $130.\nGuggenheim maintained the stock with a Buy and boosted the price target from $136 to $150\n\nConsidering buying INCY stock? Here’s what analysts think:\n\nPhoto via Shutterstock","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2655189131","isCrawlerRequest":true}